Ono Pharmaceutical Co., Ltd.

MUN:ON4 Stock Report

Market Cap: €6.1b

Ono Pharmaceutical Past Earnings Performance

Past criteria checks 3/6

Ono Pharmaceutical has been growing earnings at an average annual rate of 18.2%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been growing at an average rate of 13.5% per year. Ono Pharmaceutical's return on equity is 14.8%, and it has net margins of 24.2%.

Key information

18.2%

Earnings growth rate

19.4%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate13.5%
Return on equity14.8%
Net Margin24.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ono Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

MUN:ON4 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24500,331120,953101,792116,452
31 Mar 24502,672127,97797,389112,174
31 Dec 23498,070127,61193,791105,863
30 Sep 23489,199124,87591,302105,076
30 Jun 23460,481115,06488,400100,510
31 Mar 23447,187112,72386,64395,344
31 Dec 22428,951111,55582,77892,389
30 Sep 22403,98596,56879,40882,955
30 Jun 22380,72085,92276,89080,047
31 Mar 22361,36180,51974,11975,879
31 Dec 21345,78173,55875,88868,001
30 Sep 21332,88781,86674,45569,203
30 Jun 21321,73478,00371,37265,286
31 Mar 21309,28475,42566,61662,384
31 Dec 20302,05474,36462,47464,973
30 Sep 20293,88666,73761,27961,295
30 Jun 20293,35164,87062,82262,874
31 Mar 20292,42059,70465,19666,497
31 Dec 19290,73660,23366,77164,207
30 Sep 19293,24755,51067,52867,895
30 Jun 19291,37452,63367,54870,264
31 Mar 19288,63451,53968,00070,008
31 Dec 18284,46351,97869,04371,627
30 Sep 18284,78557,91967,96770,453
30 Jun 18272,16553,74667,13869,593
31 Mar 18261,83650,28466,35368,821
31 Dec 17256,52254,76064,97866,892
30 Sep 17248,51753,88463,96663,599
30 Jun 17246,95353,88762,84661,325
31 Mar 17244,79755,79360,66057,506
31 Dec 16236,71048,27057,39652,949
30 Sep 16207,70736,22553,70249,595
30 Jun 16183,34529,20649,85046,653
31 Mar 16160,28424,97942,62843,369
31 Dec 15140,92716,44938,70540,751
30 Sep 15143,69721,56837,11340,790
30 Jun 15139,66319,52136,24439,972
31 Mar 15135,77512,97640,82441,346
31 Dec 14137,59217,66342,57238,204
30 Sep 14133,92613,47441,29639,463
30 Jun 14137,14616,78739,68540,895
31 Mar 14143,24720,35036,90044,413
31 Dec 13145,94621,57435,55249,229
30 Sep 13145,98423,20535,09449,203

Quality Earnings: ON4 has high quality earnings.

Growing Profit Margin: ON4's current net profit margins (24.2%) are lower than last year (25%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ON4's earnings have grown by 18.2% per year over the past 5 years.

Accelerating Growth: ON4's earnings growth over the past year (5.1%) is below its 5-year average (18.2% per year).

Earnings vs Industry: ON4 earnings growth over the past year (5.1%) exceeded the Pharmaceuticals industry 1.5%.


Return on Equity

High ROE: ON4's Return on Equity (14.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies